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The diagnosis of cystic fibrosis (CF) is commonly confirmed 
by molecular genetics with the presence of specific muta-
tions of cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene. We report a case of cystic fibrosis (CF) in a 
15-year-old female patient who is a compound heterozy-
gote for CFTR gene, with delta F508 and Tyr109Glyfs muta-
tions detected. This is the first detailed description of such 
a case in the medical literature. The primary CF presenta-
tion occurred at the age of 9 in the form of gastrointestinal 
symptoms including greasy, bulky, and foul-smelling stool. 
The patient exhibited delayed growth, with her height and 
weight being below the 5th centile for age according to 
the World Health Organization growth curves. Pancreatic 
enzyme supplement treatment was started immediately, 
alongside high-fat and high-calorie diet, resulting in pa-
tient’s recovery and development. DNA analysis of CFTR 
gene demonstrated the presence of del. F508 mutation 
and a rare combining deletion and insertion mutation p. 
Tyr109Glyfs. The combination of the two mutations is very 
rare in CF patients and is therefore valuable to document 
this case in order to provide information on disease pro-
gression, therapy options, and outcomes. With standard 
treatment and early diagnosis, the patient is currently do-
ing well and is not restricted by the disease in her daily and 
sports activities.
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We report a case of a 15-year-old female patient with the 
clinical presentation of cystic fibrosis (CF) due to a rare 
compound heterozygote mutation. The combination of 
the two detected mutations and their impact on CF clinical 
presentation and progression is not described in the litera-
ture, with only 9 cases reported in the CFTR2 database (1).
CAsE rEPorT
The patient’s first hospital admission was at the age of 
9 because of poor growth, failure to gain weight even 
with increased food intake, and frequent stools (3-4 times 
a day). Her stools were periodically greasy, bulky, and 
strong-smelling. According to World Health Organization 
growth curves, the patient’s weight was in the 5th cen-
tile and height below the 5th centile for age. The patient’s 
birth history was unremarkable, with no early signs of CF. 
During the early infancy, the patient had recurrent up-
per respiratory tract infections, with constant cough and 
chronic nasal congestion treated with nebulized saline 
and occasionally oral antibiotics (when fever was present 
or expectorated mucus was purulent). Before her first vis-
it, she had never had pneumonia and had not required 
hospital treatment. At the first visit, serum liver enzymes 
were elevated (aspartate aminotransferase 64 U/L, alanine 
aminotransferase 53 U/L, gamma-glutamyl transferase 
35 U/L). Fat-soluble vitamins A, D, and E levels were de-
creased. Stool analysis detected fat droplets. Blood glu-
cose levels were within the reference range. Blood coag-
ulation parameters were just below the reference range. 
Inflammation parameters (eg, erythrocyte sedimentation 
rate, C-reactive protein, fibrinogen) were not increased. 
Abdominal ultrasound showed no abnormal findings. Ul-
trasound densitometry of both feet was normal. Pancre-
atic malabsorption was diagnosed by quantification of 
fecal elastase activity. The result was 15 µg/g, which was 
significantly low. The sweat test showed a high chloride 
level (104 mEq/L), which was confirmed when the test 
was repeated (107 mEq/L). Chest x-ray showed peribron-
chial thickening. Pulmonary function tests showed nor-
mal pulmonary function. Acid-base status showed slightly 
lowered arterial oxygen tension, with oxygen saturation 
of 96%-97%. Cystic fibrosis DNA testing was performed by 
Abbot CFv3 commercial laboratory test for 32 of the most 
common CFTR mutations, and concluded the patient was 
heterozygous for del. F508 mutation.
She was prescribed with pancreatic enzyme supplements 
(25 000 units/larger meal and 10 000 units/smaller meal) 
and fat-soluble vitamin supplements (vitamins A, D, E, K) to 
be taken daily together with a high-calorie, high-fat diet. 
With therapy, the stools normalized to 1-2 times a day and 
were only rarely greasy.
On one of her following visits, at the age of 12, she was 
coughing. Sputum analysis showed 25 polymorphonuclear 
cells with Staphylococcus aureus isolated. Oral azithromycin 
was prescribed for 5 days. Dornase alfa (human recombi-
nant DNase) was also introduced. She was advised to do 
regular physical therapy at home. Control sputum analysis 
was done after therapy and it did not show any pathogens. 
Sputum samples for sputum microbiology were obtained 
on regular patients’ check-ups, and the analysis did not re-
veal pathogens.
She was monitored yearly with a modified 2-hour oral glu-
cose tolerance test, with results within the reference range. 
Patient’s growth status improved, her weight was then in 
the 44th and her height in the 10th centile for age. She 
showed no signs of delayed puberty and had menarche at 
the age of 13, but her menstrual cycles were irregular due 
to malnutrition. Now at the age of 15, her weight is in the 
56th and her height in the 19th centile for age.
Standard pulmonary function tests showed normal pul-
monary function with forced expiratory volume 1 over 
100% on multiple follow-ups, as well as forced vital ca-
pacity (FVC). Physical examination revealed minimal signs 
of nail clubbing. Chest CT showed ectatic bronchi, thick-
ened bronchial wall, with an impaction inside the lumen 
in both upper lung lobes, the middle lobe, and the lingula 
(Figure 1).
On one of the recent check-ups, at age 15, she had symp-
toms of productive cough, especially in the morning. 
Physical examination revealed a few pulmonary base 
crackles. Chest x-ray showed acute bilateral hilar lymph-
adenopathy. Blood inflammation parameters were within 
the reference range. Bronchial aspirate analysis showed 
thick mucus with neutrophils, detritus, and bacteria: 
Staphylococcus aureus, Pseudomonas aeruginosa, and 
Candida albicans. Cardiac status was normal. She was 
prescribed oral ciprofloxacin and amoxicillin clavulanate. 
In post-therapy control sputum, Pseudomonas aeruginosa 
was isolated again. The patient is currently on aerosolized 
antibiotic therapy (tobramycin) at a 300 mg dose twice 
a day on alternate months for 6 months. She also uses 
saline nebulizer, positive pressure device to help muco-
ciliary clearance, and high-frequency chest wall oscil-
lation treatments.
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She was examined by an ear, nose, and throat specialist. 
Fiberoptic endoscopy showed hypertrophic inferior nasal 
concha, bilateral middle nasal meatus polips, and a lot of 
serous discharge. Fluticasone propionate nasal drops and 
isotonized seawater spray were introduced in the therapy 
alongside dornase alfa. Nasal congestion symptoms have 
decreased significantly.
The patient has good school attendance records and is not 
restricted in her activities (dancing and tennis). Clinical CF 
expression was evident but we wanted to support the di-
agnosis by molecular genetics. Therefore, in May 2018 the 
patient’s and parents’ blood was sent for additional geno-
typing of CFTR gene to BioGlobe, Hamburg, Germany (Ta-
ble 1). The genotyping was performed by matrix-assisted 
laser desorption/ionization time-of-flight IPLEX technol-
ogy and Sanger sequencing. The first mutation was del. 
F508 and the second was a combined deletion and inser-
tion mutation. The three bases TAT were replaced by a G, 
resulting in a change from tyrosine in codon 109 to gly-
cine and a subsequent stop codon due to frameshift. Pa-
rental genotypes showed that the father was a heterozy-
gous carrier for the mutation delta F508, whereas the 
mother was a heterozygous carrier for the mutation 
c.325_327delTATinsG, TAT/G het p.(Tyr109Glyfs), confirm-
ing the diagnosis by molecular genetics.
DisCussion
The sequencing of patient’s and parents’ CFTR genotype 
confirmed the CF diagnosis, showing that our patient is 
a compound heterozygote with delta F508 and Tyr109-
Glyfs mutations detected. The two mutations acting in-
trans result in the CF phenotype. Del. F508 is present in 
70% of patients with CF (2), while p. Tyr109Glyfs is quite 
rare. It was first reported in a 3-year-old female patient in 
Slovenia with a severe form of the disease in 1993 and ac-
counted for 1.1% of all the mutations found in 90 Hungar-
ian CF patients in 2015 (3). Tyr109Glyfs mutation leads to 
a frameshift and terminates the translation at amino acid 
112 of CFTR (4). The literature shows little data on these 
two mutations occurring together. CFTR2 database has 
records of only 9 patients with this gene combination 
(1). The average sweat chloride level in these 9 patients 
was 118 mEq/L, compared with 96 mEq/L in patients with 
two CF-causing variants. A total of 89% of patients with 
the rare mutations were suffering from pancreatic insuffi-
ciency, compared with 85% patients with two CF-causing 
TAblE 1. Gene analysis for 37 most common mutations of CFTR gene by matrix-assisted laser desorption/ionization time-of-flight 
iPlEX technology and sanger sequencing.
CFTR gene mutation Comment
Father del. F508 Heterozygous carrier of a CF*-causing mutation
Mother c.325_327delTATinsG (p.Tyr109Glyfs) Heterozygous carrier of a CF-causing mutation
Patient • c.325_327delTATinsG (p.Tyr109Glyfs)
• del. F508
Compound heterozygote for CFTR if the mutations 
are located on different parental chromosomes
*CF – cystic fibrosis.
FiGurE 1. High-resolution computed tomography of the thorax showing ectatic bronchi. Thickened bronchial wall, with an impac-
tion inside the lumen in both upper lung lobes, the middle lobe, and the lingula, is visible. lymphadenopathy or pleural effusion is 
not visible.
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variants. Furthermore, 44% of patients had Pseudomonas 
infection in comparison with 55% of patients with two 
CF-causing variants (1). There is insufficient lung function 
data for comparison. Although these results suggest that 
this rare mutation has poor clinical manifestations, our 
patient had a milder form of CF without severe lung in-
fections and functions well in daily life, which is a novelty 
in itself and shows why early diagnosis and proper treat-
ment is crucial when it comes to clinical outcomes. Com-
pound heterozygosity involving the two mutations prob-
ably led to a somewhat less severe clinical manifestation 
of CF in our patient, which is rare when compared with 
other patients with these mutations. This confirms that 
phenotype-genotype determination of pathogenic mu-
tations should be favored over genetic-phenotype de-
termination of disease, especially because of scarcity of 
patients with this variant (1,5). We reinforce the recom-
mendation for a wide mutation screening panel for pa-
tients with CF, considering the potential benefits of early 
recognition and treatment. Also, we strongly recommend 
to record useful patient data in databases like CFTR2 to 
ensure better treatment and diagnosis. Due to the pau-
city of literature information regarding patients with these 
two genetic variants, we believe that documenting and 
studying the case of this patient will provide information 
on therapy options and outcomes in future cases with the 
same genetic variant.
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